share_log

Transcode Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-Thomas A. Fitzgerald(5.5%)

Transcode Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-Thomas A. Fitzgerald(5.5%)

Transcode Therapeutics | SC 13D：超過5%持股股東披露文件-Thomas A. Fitzgerald(5.5%)
美股sec公告 ·  06/22 04:09
牛牛AI助理已提取核心訊息
Thomas A. Fitzgerald, the Interim CEO, CFO, and a board member of TransCode Therapeutics, Inc., filed a Schedule 13D with the SEC on June 21, 2024, indicating a significant ownership stake in the company. Fitzgerald reported beneficial ownership of 422,036 shares of TransCode Therapeutics' common stock, which represents approximately 5.5% of the company's outstanding shares. This stake includes 1,408 shares held directly and 420,628 shares issuable upon the exercise of stock options within 60 days of the filing date. The filing, which details Fitzgerald's potential influence over corporate activities, also notes his right to acquire additional shares or dispose of his holdings in the future. Fitzgerald's investment decisions are expected to be influenced by a variety of factors, including the company's business prospects and market conditions.
Thomas A. Fitzgerald, the Interim CEO, CFO, and a board member of TransCode Therapeutics, Inc., filed a Schedule 13D with the SEC on June 21, 2024, indicating a significant ownership stake in the company. Fitzgerald reported beneficial ownership of 422,036 shares of TransCode Therapeutics' common stock, which represents approximately 5.5% of the company's outstanding shares. This stake includes 1,408 shares held directly and 420,628 shares issuable upon the exercise of stock options within 60 days of the filing date. The filing, which details Fitzgerald's potential influence over corporate activities, also notes his right to acquire additional shares or dispose of his holdings in the future. Fitzgerald's investment decisions are expected to be influenced by a variety of factors, including the company's business prospects and market conditions.
TransCode Therapeutics臨時首席執行官、首席財務官和董事Thomas A. Fitzgerald於2024年6月21日向SEC提交了13D表格，表示持有該公司的重要股權。Fitzgerald報告了422,036股TransCode Therapeutics普通股的受益所有權，這相當於該公司流通股的約5.5%。這一股權包括直接持有的1,408股和在提交日期60天內行權的420,628股期權。文件還詳細記錄了Fitzgerald在公司活動中的潛在影響，以及他未來獲得更多股份或處置其持股的權利。Fitzgerald的投資決策預計會受到多種因素的影響，包括公司的業務前景和市場狀況。
TransCode Therapeutics臨時首席執行官、首席財務官和董事Thomas A. Fitzgerald於2024年6月21日向SEC提交了13D表格，表示持有該公司的重要股權。Fitzgerald報告了422,036股TransCode Therapeutics普通股的受益所有權，這相當於該公司流通股的約5.5%。這一股權包括直接持有的1,408股和在提交日期60天內行權的420,628股期權。文件還詳細記錄了Fitzgerald在公司活動中的潛在影響，以及他未來獲得更多股份或處置其持股的權利。Fitzgerald的投資決策預計會受到多種因素的影響，包括公司的業務前景和市場狀況。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。